NCT05594147View on ClinicalTrials.gov

An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib

CompletedOBSERVATIONAL
Enrollment

4,103

Participants

Timeline

Start Date

October 31, 2022

Primary Completion Date

April 21, 2023

Study Completion Date

April 21, 2023

Conditions
Malignant Solid TumorsCoronavirus Disease 2019 (COVID-19)SARS-CoV-2 Infection
Interventions
DRUG

Non-TKIs

Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

DRUG

Other TKIs

Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

DRUG

Regorafenib (Stivarga, BAY73- 4506)

Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

DRUG

Sorafenib (Nexavar, BAY43-9006)

Retrospective cohort analysis, using IBM MarketScan and Optum Clinformatics database in the US.

Trial Locations (1)

07981

Bayer, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05594147 - An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib | Biotech Hunter | Biotech Hunter